Table 1.
Patient characteristics
| total n=64 | [n] | % |
|---|---|---|
|
| ||
| Age [years] | ||
| Median (Range) | 52 (31; 68) | |
|
| ||
| Subtype | ||
| Invasive ductal | 55 | 86 |
| Invasive lobular | 8 | 13 |
| Mixed ductulo-lobular | 1 | 1 |
|
| ||
| Grade | ||
| G2 | 17 | 27 |
| G3 | 47 | 73 |
|
| ||
| Estrogen receptor status | ||
| Positive (≥1% positive tumor cells) | 41 | 64 |
| Negative | 23 | 36 |
|
| ||
| Progesterone receptor status | ||
| Positive (≥1% positive tumor cells) | 24 | 37 |
| Negative | 40 | 63 |
|
| ||
| HER2 status | ||
| Positive (IHC 3+ or FISH ratio ≥2.2) | 23 | 36 |
| Negative (IHC 0, 1+ or FISH ratio <2.2) | 37 | 58 |
| n/a | 4 | 6 |
|
| ||
| Surgical procedure | ||
| Breast conserving therapy | 33 | 52 |
| Mastectomy | 31 | 48 |
|
| ||
| ypT | ||
| 0 | 9 | 14 |
| 1 | 26 | 41 |
| 2 | 17 | 27 |
| 3 | 10 | 15 |
| 4 | 2 | 3 |
|
| ||
| ypN | ||
| 0 | 26 | 41 |
| 1 | 13 | 20 |
| 2 | 16 | 25 |
| 3 | 6 | 9 |
| n/a | 3 | 5 |
|
| ||
| Pathologic response after Chemotherapy | ||
| pCR | 9 | 14 |
| non-pCR | 55 | 86 |
|
| ||
| Follow-up [months] | ||
| Mean (95% confidence interval) | 116 (100; 131) | |
| Median (Range) | 112 (104; 120) | |
|
| ||
| Disease-free survival [months] | ||
| Mean (95% confidence interval) | 82 (68; 95) | |
| Median (Range) | 125 (52; 197) | |
|
| ||
| Overall survival [months] | ||
| Mean (95% confidence interval) | 103 (91; 115) | |
| Median (Range) | 115 (94; 135) | |
ypT, tumor stage assessed in the surgical specimen after neoadjuvant chemotherapy
ypN, nodal stage assessed in the surgical specimen after neoadjuvant chemotherapy
pCR, no residual invasive tumor in the breast, with or without residual non-invasive intraductal carcinoma, and irrespective of lymph node status (ypT0/is, ypNx)